Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USA
Our analysis suggests that efanesoctocog alfa was dominant versus prophylaxis with standard and elevated factor VIII extended half-life dosing regimens. Efanesoctocog alfa was associated with better joint health and, hence, contributed to fewer bleeds, lower costs, and higher quality-adjusted life-years.
Authors
- Ion Agirrezabal (ORCID: https://orcid.org/0000-0003-3170-7845)
- Alix Arnaud (ORCID: https://orcid.org/0000-0003-1193-4258)
- Amy Dymond (ORCID: https://orcid.org/0000-0002-8519-6537)
- William D. Green (ORCID: https://orcid.org/0000-0001-8556-0389)
Institutions
- Leeds and York Partnership NHS Foundation Trust (GB)
- Sanofi (Spain) (ES)
- Sanofi (United States) (US)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1007/s40273-025-01556-2
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi